Clinical trials: HIV Infections
HIV Infections
Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients
The primary objective was to evaluate the antiviral activity and safety of two regimens of tipranavir (500 mg BID or 1000 mg BID) plus ritonavir (100 mg BID) administered in combination with 1 new nucleoside reverse transcriptase…
- Trial name
- NCT02238314
- Testing
- Tipranavir low dose, Tipranavir high dose, Ritonavir
- Volunteers
- 41 people
- Sponsor
- Boehringer Ingelheim
Vaccine Response
Study of Safety and Immunogenicity of HIV Vaccines in Healthy Volunteers
Background: Vaccines create resistance to disease. This study tests experimental human immunodeficiency virus (HIV) vaccines that use an adenovirus as a transporter.
- Trial name
- NCT01989533
- Testing
- Ad4-mgag, Ad4-EnvC150, gp 120 Protein Boost
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Alcohol Dependence, HIV/AIDS
Targeting Non-virally Suppressed Adults With Alcohol Use Disorder in HIV Primary Care
The proposed pilot study is a randomized feasibility trial of technology-enhanced brief intervention for drinking reduction and antiretroviral therapy (ART) adherence in 60 non-virally suppressed HIV participants who meet…
- Trial name
- NCT04280068
- Testing
- Clinician Guide (CG), Clinician Guide plus HealthCall
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Research Foundation for Mental Hygiene, Inc.
HIV Infections
Acupuncture and Moxa: A Randomized Clinical Trial for Chronic Diarrhea in HIV Patients
The objective of this study is to test alternative treatment strategies to reduce the frequency of chronic diarrhea among HIV positive individuals. 60 percent of patients with HIV disease in the U.S.
- Trial name
- NCT00010491
- Testing
- Acupuncture, Moxibustion
- Where
- United States
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
HIV Infection
Integrase Resistance Analysis in HIV Patients Who Interrupted Raltegravir Due to Incomplete Viral Suppression
Prospective study to evaluate the potential persistent viral effect of raltegravir in 20 treatment experienced HIV patients with incomplete viral suppression
- Trial name
- RAL-dyn (NCT00787774)
- Testing
- resume raltegravir
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Hospital Clinic of Barcelona
HIV-1-infection
Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women
The goals of this clinical study are to learn more about the study drugs, VRC07-523LS, CAP256V2LS, and vesatolimod (VES) and how safe it is in women that have HIV and are on antiretroviral therapy (ART).
- Trial name
- NCT05281510
- Testing
- Vesatolimod, VRC07523LS, CAP256V2LS
- Where
- South Africa
- Volunteers
- 20 people
- Sponsor
- Gilead Sciences
HIV Infections
A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Patients With AIDS Related Complex (ARC)
The objective is to determine the effect of Isoprinosine (inosine pranobex) in homosexual male patients with AIDS related complex (ARC) in delaying the onset of AIDS.
- Trial name
- NCT00002060
- Testing
- Inosine pranobex
- Where
- United States
- Sponsor
- Newport Pharmaceuticals International
HIV Infections, HIV Seronegativity
Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia
Tenofovir disoproxil fumarate (also known as tenofovir DF or Viread) is used with other anti-HIV drugs to treat HIV infection. Taking tenofovir DF every day may also prevent HIV infection.
- Trial name
- NCT00078182
- Testing
- Tenofovir DF
- Where
- Cambodia
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Extended Follow-Up of the ISS T-003 Trial Volunteers (ISS T-003 EF-UP2020)
A further extension of the follow-up of the volunteers of the ISS T-003 trial is being conducted in order to evaluate the persistence of vaccine immunogenicity as well as of the immunological and virological effects induced by…
- Trial name
- T003EFUP2020 (NCT05680948)
- Where
- South Africa
- Volunteers
- 179 people
- Sponsor
- Istituto Superiore di Sanità
HIV Infections
Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial
Primary objective: Evaluation of the efficacy of TDF+3TC+EFV versus TDF+EFV QD to maintain plasma HIV-1 RNA BLQ (< 50 copies/mL) (c/mL) at 48 weeks (W48) Main Secondary objectives: Comparison of the two arms for genotypic…
- Trial name
- COOL (NCT00643968)
- Testing
- EFV+TDF, EFV+3TC+TDF
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Gilead Sciences
Healthy, HIV
A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074
This is a phase 1 clinical trial to evaluate the safety, pharmacokinetics and the antiretroviral effects of the highly neutralizing anti-HIV-1 monoclonal antibody 10-1074 in HIV-infected and HIV-uninfected individuals.
- Trial name
- NCT02511990
- Testing
- 3 mg/kg, single dose IV administration of 10-1074, 10 mg/kg, single dose IV administration of 10-1074, 30 mg/kg, single dose IV administration of 10-1074
- Where
- 2 sites in United States, Germany
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
HIV/AIDS
Contribution of "Praise Messages" to HIV Treatment Retention and Adherence Among Female Sex Workers in Ethiopia
This study evaluates the effects of praise message phone calls on antiretroviral therapy (ART) initiation, adherence, and prescription refills.
- Trial name
- NCT03127397
- Testing
- Praise message phone call
- Where
- Ethiopia
- Volunteers
- 810 people
- Sponsor
- Reed College
HIV
Clinical Study of an Aluvia-based HAART Regimen for Prevention of Mother-to-child HIV Transmission in Africa
Therapeutic options to prevent vertical transmission of HIV remain limited. Combination antiretroviral therapy in the form of HAART (Highly Active Anti Retroviral Therapy) is generally recommended in the developed world, both for…
- Trial name
- NCT01088516
- Testing
- Lopinavir/Ritonavir (200/50 mg) Tablets + Zidovudine + 3TC
- Where
- Zambia
- Volunteers
- 280 people
- Sponsor
- University of Zambia
HIV
Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia
One hundred subjects in Russia will be treated with a combination of Combivir (zidovudine and lamivudine) and maraviroc as their first line HIV therapy.
- Trial name
- NCT01275625
- Testing
- HIV therapy
- Where
- 8 sites in Russia
- Volunteers
- 98 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Study of Disease Progression and Anti-HIV Treatments
To determine the influence of virus load, CD4 count, biologic phenotype, and presence of symptomatic disease on the response of HIV-infected patients to a new therapeutic regimen.
- Trial name
- NCT00001068
- Testing
- Lamivudine
- Where
- 41 sites in United States, Puerto Rico and 1 more
- Volunteers
- 210 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B, HIV
Integrating Hepatitis B Elimination Into the HIV Program in Zambia
The goal of this study is to develop an integrated HBV-HIV service care model in Zambia by working with people living with HBV, healthcare workers, policy makers and other key stakeholders to co-design an intervention.
- Conditions
- Hepatitis B, HIV, Implementation Science
- Trial name
- INTEGRATE B (NCT07875218)
- Testing
- Integrated HBV/HIV Service Delivery Model
- Where
- Zambia
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
HIV Infection
Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy
This study is an evaluation of the safety of 625 mg formulation when administered to HIV-infected pregnant women from their second trimester through six weeks postpartum.
- Trial name
- NCT00246610
- Testing
- Nelfinavir mesylate, 625 mg
- Where
- 6 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- Pfizer
HIV-Associated Lipodystrophy Syndrome
Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients
Highly active antiretroviral therapy (HAART) has improved the long time survival of HIV infected individuals. However an increasing number of HIV-patients have developed metabolic and morphological alterations including…
- Trial name
- NCT00135460
- Testing
- nucleoside analogue sparing HAART regimen
- Where
- 5 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Danish HIV Research Group
Asymptomatic HIV, HIV Infections
ID and Testing Via Friendship Networks
This is a pilot study with a cross-sectional research design to recruit Hispanic/Latina and African American adolescent and young adult women, aged 13-24 years to serve as index recruiters, who will in turn recruit members of her…
- Trial name
- NCT00841360
- Testing
- Index Recruiter, Friendship Network Member
- Where
- 3 sites in United States
- Volunteers
- 535 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
HIV Pre-exposure Prophylaxis
Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)
The goal of this clinical study is to learn more about the study drug lenacapavir (LEN), safety, tolerability, and pharmacokinetics (how LEN is absorbed, modified, distributed, and removed from the body of the participants) of…
- Trial name
- PURPOSE 365 (NCT07047716)
- Testing
- Lenacapavir Injection, Lenacapavir Tablet
- Where
- 31 sites in United States
- Volunteers
- 339 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.